- PLN124.93m
- PLN143.63m
- PLN15.76m
Ryvu and TIM to enter Warsaw's mWIG40 index
Brief: Mabion Signs EUR 3.2 Mln Deal For Delivery Of Bioreactors
Brief: Poland's Mabion Q1 Net Profit Up At 16.5 Mln Zlotys
Brief: Mabion Reduces Number Of Bioreactors Under Deal With Adolf Kühner
Brief: Mabion Terminates Deal With Parexel International For MabionCD20 Clinical Trial
Brief: Mabion AGM To Vote On Retaining 2022 Net Profit
Brief: Mabion Ends Patent Procedures Within MabionMS Project
Brief: Mabion FY Net Profit Up At 23.2 Mln Zlotys
Brief: Mabion Estimates Capex At About 90-100 Mln Zlotys In 2023-24 under new strategy
Brief: Mabion Signs Second Annex With Novavax On Omicron Variant
Brief: Mabion Signs Statement Of Work #10 With Novavax For Logistics Services
Brief: Mabion Terminates Agreement With PFR On Investment
Brief: Mabion Signs $15 Mln Loan Deal With EBRD
Brief: Mabion Q3 Net Loss Narrows To 5.1 Mln Zlotys
Brief: Mabion Extends Cooperation With Novavax
Brief: Mabion Terminates Subsidy Deal For Expansion Of R&D Centre
Brief: Mabion Says EBRD Credit Committee Approves Granting $15 Mln Loan To Company
Brief: Mabion Q2 Net Loss Turns To Profit Of 5.1 Mln Zlotys
Brief: Mabion Expands And Extends Deal With Novavax Till End-2026